Seelos Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Seelos Therapeutics generated cash of -$23,912,000, which is more than the previous year. Cash used in financing activities reached the amount of $11,375,000 last year. Net change in cash is therefore -$12,537,000.
Cash Flow
| 2014 | -18.01M | 145K | 7.86M |
|---|---|---|---|
| 2015 | -22.64M | -332K | 15.46M |
| 2016 | -13.06M | 265K | 0 |
| 2017 | -10.46M | 12.20M | 2.50M |
| 2018 | -8.12M | -3K | 5.37M |
| 2019 | -19.30M | 5.92M | 29.52M |
| 2020 | -20.91M | 6.36M | 26.31M |
| 2021 | -48.99M | 0 | 112.06M |
| 2022 | -61.60M | 0 | -1.59M |
| 2023 | -23.91M | 0 | 11.37M |
SEEL Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 15.53M | 78.73M | 15.66M | 10.26M | 42K | 6.33M | 2.08M | 3.88M | 11.4M | 21.40M |
Operating activities | ||||||||||
Net income | -37.88M | -73.53M | -66.04M | -19.10M | -51.25M | -9.21M | -11.74M | -7.43M | -19.02M | -22.47M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 57K | 53K | 1.58M | 150K | 0 | 41K | 117K | 289K | 300K | 170K |
Stock-based compensation expense | 3.98M | 5.07M | 8.34M | 2.04M | 459K | 0 | 1.13M | 1.74M | 1.21M | 1.73M |
| Deferred income tax benefit | 3.98M | 5.07M | 8.34M | 2.04M | 459K | 0 | 1.13M | 1.74M | 1.21M | 1.73M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -11K | 159K | -620K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -295K | -194K | 61K |
Accounts payable | 12.77M | 1.93M | -194K | 1.09M | -1.42M | 177K | -705K | -509K | 609K | -66K |
Cash generated by operating activities | -23.91M | -61.60M | -48.99M | -20.91M | -19.30M | -8.12M | -10.46M | -13.06M | -22.64M | -18.01M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 6.36M | 5.92M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -18K | -337K | -580K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3K | 5K | 50K |
Cash generated by investing activities | 0 | 0 | 0 | 6.36M | 5.92M | -3K | 12.20M | 265K | -332K | 145K |
Financing activities | ||||||||||
Common Stock Issued | 20.11M | 457K | 118.16M | 26.12M | 25.00M | 4.79M | 10.73M | 0 | 10.86M | 5.91M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -1.19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -42K |
Repayments of term debt | -7.64M | -1.88M | -13.55M | -147K | 0 | -1.36M | -7.12M | 0 | 4.49M | -2.77M |
Cash used in financing activities | 11.37M | -1.59M | 112.06M | 26.31M | 29.52M | 5.37M | 2.50M | 0 | 15.46M | 7.86M |
Net Change In Cash | -12.53M | -63.20M | 63.07M | 5.40M | 10.21M | -2.75M | 4.24M | -1.8M | -7.51M | -10.00M |
Cash at end of period | 2.99M | 15.53M | 78.73M | 15.66M | 10.26M | 3.57M | 6.33M | 2.08M | 3.88M | 11.4M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |